Background: Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. WSG-AGO epiribicine and cyclophosphamide (EC)-Doc is a large trial evaluating modern taxane-based chemotherapy in patients with 1-3 positive lymph nodes (LNs) only.
introduction WSG-AGO epiribicine and cyclophosphamide (EC)-Doc is one of the first-generation trials comparing taxane versus nontaxane-based regimens ( Figure 1 ). When the trial was planned, early results from CALGB 9344 suggested superiority of sequential taxanes (4 × doxorubicine (A) and cyclophosphamide (C) (AC) → 4 × paclitaxel) over four courses of AC in node-positive (N+) breast cancer (BC) [1] . In contrast to the original CALGB regimen, WSG EC-Doc trialists decided to replace doxorubicin by epirubicin and to use less neurotoxic docetaxel instead of paclitaxel [2] . The control represents the national standard at that time, which preferred 5-fluorouracil (F), epirubicin (E), and cyclophosphamide (C) (FE 100 C) but still allowed CMF (a combination of cyclophosphamide, methotrexate, and 5-fluorouracil). Only N1 patients were eligible, since the question was whether better survival would outweigh additional toxicity and longer chemotherapy duration in this intermediate-recurrence-risk population. According to the St Gallen Consensus at that time, adjuvant chemotherapy was routinely advised in all N+ tumors, independently from extent of nodal involvement. Beyond tumor burden, later Consensus considered tumor biology to be another important discriminator for adjuvant decision making. Particularly proliferation markers (Ki-67) were recommended for identification of luminal A-like tumors with excellent prognosis potentially over-treated with chemotherapy [3] .
In addition to the outcome data, therefore, we investigated retrospectively potential immunohistological predictors of taxane outcome on a representative tumor bank subset [3] [4] [5] .
methods eligibility criteria
Eligible patients were 18-65 years old and had histologically proved BC, pT1-3 with 1-3 positive lymph nodes (LNs). M0 status had to be proved by chest X-ray, liver ultrasound, and bone scan. Surgical requirements included free margins and >10 removed LNs. Patients were eligible with a performance status eastern cooperative oncology group <2; patients with major organ dysfunction, preexisting peripheral polyneuropathy, pregnancy, or inflammatory/sequential BCs were excluded. Enrollment within 42 days of surgery was mandatory. Written informed consent was obtained before randomization. The protocol and central tumor bank sub-study was approved by local ethics committee/institutional review boards and conducted according to the Declaration of Helsinki and European GCP criteria.
Randomization was carried out according to a stratified permuted-block design, with center as the sole stratification factor.
treatment
In the control arm, it was at the discretion of the investigating center to give six cycles CMF ( stimulating factor was recommended at onset of taxanes. Endocrine therapy and radiotherapy were given according to the national guidelines [6] . When the HERA trial started in 2001, EC-Doc trial was accepted as a feeder trial.
follow-up
Follow-up examinations were carried out at 3-month intervals for 2 years and at 6-month intervals thereafter.
central tumor bank sub-study 
F 500 E 100 C 500 T Associations among discrete variables were assessed by Fisher's exact test. Secondary end points were overall survival (OS) toxicity and quality of life (QoL). In QoL analysis, patients with missing data were excluded (missingat-random hypothesis). Differences in mean Global Health Status scores were assessed by two-sided T-tests. Binary variable Ki-67 20 was defined using 20% cutoff (≥ versus <) for the distinction of A-versus B-like subtypes.
findings patient characteristics
From April 2000 to August 2005, 2012 patients were enrolled in 165 centers, and 1950 (97%) were eligible for ITT analysis. Main reasons for ineligibility were missing informed consent and severe violation of inclusion criteria. For the control arm, 152 centers opted for FEC, 13 for CMF; 177 (9%) patients were assigned to CMF. For ITT analysis, 978 EC-Doc and 972 control (FEC/CMF: 795/177) patients were included. There are no significant differences in baseline characteristics between the study arms (see Table 1 below). Median age was 52. Two-thirds Table 2 ).
Concerning the primary end point (EFS), superiority of ECDoc versus control by ITT was demonstrated (P = 0.013) according to the planned one-sided log-rank test (two-tailed P = 0.026; Figure 2A) ; estimated 5-year EFS rates for EC-Doc and control were 89.8% versus 86.6%. Comparing EC-Doc with FEC alone also suggested superiority of EC-Doc (one-tailed P = 0.038, two-tailed P = 0.076; log-rank; Figure 2B) 
protocol adherence
In the EC-Doc arm, 794 patients (81.2%) completed all eight cycles, and in the control arm, 870 patients completed all six cycles: FEC 721 (90.7%); CMF 149 (84.2%). Figure 3 shows detailed discontinuation information. Dose reductions >25% were reported for 182 cycles involving n = 104 patients (10.6%) from EC-Doc versus 43 cycles involving n = 29 patients (3%) from FEC/CMF. Nine (EC-Doc) and 12 patients (control) received trastuzumab in the HERA trial.
toxicity Supplementary Table S2 , available at Annals of Oncology online summarizes grade 3/4 (NCI-CTC v2.0) toxicity by cycle and patient. In terms of acute toxicity, EC-Doc causes significantly more anemia and thrombocytopenia. Febrile neutropenia incidence reported as adverse event was 3.7% for EC-Doc versus 2.1% for FEC. EC-Doc caused significantly more mucositis, arthralgia, pain, and neuropathy, with a marked increase when changing from EC to docetaxel. Neurotoxicity was documented during chemotherapy, persisting polyneuropathy during follow-up. The protocol suggested a 25% dose reduction in case of°2 and discontinuation in ≥°3 neuropathy. By end of therapy, neurotoxicity of any grade (°3/4) was reported in 19.1% (4.0%) of patients receiving EC-Doc versus 6.5% (1.0%) of control.
Long-term neurotoxicity (any grade) in the EC-Doc arm was documented in 14.2% of patients after 6 months, 11.0% after 1 year, and 7.4% after 2 and 3 years. Persisting peripheral neuropathy (any grade) after 2 years of follow-up was reported in 3.2% for EC-Doc (FEC 0.6%).
Chemotherapy-induced amenorrhea was recorded in a representative subgroup of premenopausal women from both arms (EC-Doc: 106 and control: 103). Amenorrhea rates were nonsignificantly higher in the EC-Doc arm (74% versus 62%, P = 0.06). Due to the small sample size, this subgroup does not qualify for survival analysis. 
interpretation
The WSG-AGO EC-Doc data have confirmed superiority of EC-Doc in terms of EFS and OS to FE 100 C/CMF in patients with 1-3 involved LNs. The effects were independent of age, hormone, and HER2 receptor status and grading. Due to the trial design there are several limitations, the data only refer to patients younger than 65 and testing is one-sided since inferiority of EC-Doc is not clinically relevant, due to its higher toxicity, longer duration and higher costs. Furthermore, CMF is considered as a weak comparator according to the EBCTG meta-analysis [7] . Therefore, two important issues raise: whether CMF/FE 100 C is an adequate control and how EC-Doc compares to other taxane-based standards.
Only 9% of patients received CMF and since the evaluation of the FEC subset (91%) confirmed superiority of EC-Doc, the control arm discussion will focus on FE 100 C. FE 100 C was chosen because it is a widely used standard in Germany, shorter and less toxic than Canadian FE 120 C, but still allowing a reasonable dose-intensity for epirubicin.
Two other large randomized trials ADEBAR [8] (6 × FE 120 C versus 4 × EC-4 × Doc) and TACT [9] (8 × FE 60 C versus 4 × FE 60 C-4 × Doc) using FEC with higher/lower cumulative doses of anthracyclines neither detected significant survival benefit from addition of taxanes. Early results from MA-21 confirm equi-effectivity of Canadian FE 120 C with E 120 Cq2w → paclitaxel × 4 q3w [10] . French FE 100 C, used here, was compared, in PACS-001, with 3 × FE 100 C-3 × Doc in N+ BC. The results of the PACS-001 trial confirm the superior outcome of the EC-Doc trial in the taxane-containing arm [11] . In summary, therefore, FE 100 C seems to be a reliable comparator though potentially inferior to FE 120 C.
Another concern is the relative efficacy of our experimental arm, compared with current anthracyline/taxane standards. Sparano et al. [12] demonstrated superior disease-free survival in patients receiving AC-Doc q3w (HR 1.23) and those receiving AC → paclitaxel weekly (HR 1.27) compared with AC → paclitaxel 175 q3w. CALGB-9741 demonstrated superiority of q2w versus q3w scheduling of AC → paclitaxel in N+ BC [13] . This dose-dense regimen is equivalent to 6 × docetaxel (T), doxorubicine (A) and cyclophosphamide (C) (TAC) in another trial [14] and 6 × TAC is as good as EC-Doc in BCIRG 005. In summary, EC-Doc is therefore one of the adequate taxane-based standard.
Nevertheless, in our trial, absolute survival differences are small and toxicity profile is a reasonable second discriminator for choosing an adjuvant regimen. Our data demonstrate that even after 1 year, QoL parameters are negatively influenced by EC-Doc, and a higher rate of chemotherapy-induced amenorrhea-probably due to longer therapy duration-must be taken into account. In terms of long-term neurotoxicity, BCIRG-005 trial [15] (AC-Doc versus 6 × TAC) reports more grade 3-4 neurotoxicity (1.5% versus 0.3%) for AC-Doc. In our own trial, we observed grade 3-4 neurotoxicity in 3.8% of patients for ECDoc, which is comparable to other studies. Weekly paclitaxel generates more grade 2-4 neuropathy (27% versus 20%) than 3-weekly paclitaxel [12] . Concerning cardiotoxicity, correlation of grade 3-4 toxicity with cumulative anthracycline doses is well documented. Ten-year data from BCIRG 001 [16] comparing TAC versus 5-fluorouracil (F), doxorubicine (A) and cyclophosphamide (C) (FAC) report grade 3-4 cardiotoxicity in 3% versus 2%, respectively. In the same trial, six and three cases of leukemia/myelodysplastic syndrome (MDS) were reported for TAC and FAC, respectively. Retrospective analysis of NCCN data does not document a relevant increase of leukemia/MDS rates by the addition of taxanes [17] .
In summary, our 5-year OS of 94.5% (EC-Doc) and 92.8% (FEC) can be considered excellent and reported toxicity compares reasonably with other taxane-containing regimens.
Nevertheless, our present biological understanding implies over-treatment with taxanes or chemotherapy in general, especially in HR+ disease, where genomic signatures identify low-risk subgroups in up to 62% of cases [18] .
Since these genomic tests are not yet routinely available, the International St Gallen Consensus has suggested to use Ki-67 in HR+ tumors as an interim surrogate marker for distinguishing luminal A-versus B-like subtypes [3] . A recently published meta-analysis demonstrated, using multivariate analysis, that Ki-67 is an excellent prognosticator, but not a predictor of chemotherapy benefit [19] . Several retrospective analyses found luminal B-like subtype to be a significant predictor for docetaxel benefit [4, 5, 20] . In contrast, Martín et al. [21] did not find any difference for FEC → weekly paclitaxel over FEC alone in the high-Ki-67 group. In the present study, luminal B-like subtype defined by a 20% Ki-67 cutoff as in PACS-01 [5] was predictive for EC-Doc benefit; 61% of HR+ tumors were luminal A-like and had excellent 5-year EFS of 93.5%, irrespective of chemotherapy regimen. In contrast, patients with luminal B-like tumors derived substantial benefit from EC-Doc (61% risk reduction).
In conclusion, our retrospective analysis of a representative patient subset using central Ki-67 for luminal sub-typing suggests that taxanes may be omitted in a substantial number of patients with hormone-sensitive, luminal A-like disease with limited nodal involvement. Clinical utility of this statement will increase with further standardization of Ki-67 and should be re-evaluated when PAM 50 becomes routinely available.
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